196078-30-5 Usage
Description
Pramlintide acetate is an injectable human amylin analog that has been developed for the treatment of both type 1 and type 2 diabetes, in conjunction with insulin. It is a 37-amino acid peptide with modifications that improve solubility and eliminate aggregation, making it a stable synthetic analog suitable for pharmaceutical use. Pramlintide acetate mimics the mechanism of action of amylin, a neurohormone cosecreted with insulin from pancreatic β cells, and is involved in glucose homeostasis.
Uses
Used in Diabetes Treatment:
Pramlintide acetate is used as an adjunct therapy for insulin-dependent diabetes, particularly for type 1 and type 2 diabetes. It helps in lowering postprandial glucose levels by inhibiting glucagon and restraining the vagus-mediated rate of gastric emptying, which slows intestinal carbohydrate absorption. Additionally, it induces postprandial satiety, resulting in weight loss in patients with type 2 diabetes.
Used in Pharmaceutical Industry:
Pramlintide acetate is used as an active pharmaceutical ingredient in the development of drugs for diabetes management. Its brand name is Symlin (Amylin), and it is a white solid with specific chemical properties that make it suitable for pharmaceutical applications.
Please note that Pramlintide acetate is contraindicated in patients with gastroparesis, those taking drugs that alter gastrointestinal motility or slow down the intestinal absorption of nutrients, and patients with hypoglycemic tendencies. The most commonly reported adverse events include nausea, vomiting, anorexia, headache, abdominal pain, fatigue, dizziness, coughing, and pharyngitis.
Clinical Use
Pramlintide acetate is a synthetic analogue of amylin (a 37-peptide) with proline substitutions at
residues 25, 28, and 29. These substitutions change its physical properties such that it is
commercially available for SC injection. When pramlintide is used in combination with insulin, it
slows gastric emptying, lowers blood glucose levels after meals, and affords a feeling of fullness
that leads to decreased caloric intake and the potential for weight loss. Pramlintide has been
approved for use in adults with type I or type II diabetes as an adjunct along with insulin. The
dose is quite different for type I (15–60 μg SC before meals) and type II diabetes (60–120 μg).
The drug should be refrigerated before opening and may be kept at room temperature for up to
28 days after opening.
Check Digit Verification of cas no
The CAS Registry Mumber 196078-30-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,0,7 and 8 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 196078-30:
(8*1)+(7*9)+(6*6)+(5*0)+(4*7)+(3*8)+(2*3)+(1*0)=165
165 % 10 = 5
So 196078-30-5 is a valid CAS Registry Number.
InChI:InChI=1/C171H269N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114(73-276)211-168(273)133(87(18)228)216-139(244)84(15)191-164(269)131(85(16)226)217-153(258)108(65-124(179)237)204-158(263)115(74-277)210-140(2